“MIRA is a space-saving solution designed to help hospitals and ambulatory surgery centers leverage their existing infrastructure to perform surgery efficiently while offering a low total cost of ownership,” said Amy Len Kobe, Principal with Baird Capital. “Consistent with our venture team’s investment goals, the MIRA platform has the ability to improve care for patients, physicians, providers, and payors. And, best of all, it’s unlike any other surgical robotic platform available today.”
Funding from the round will also be used to support the company’s research and development pipeline. Beyond its initial device design for colon resection, Virtual Incision has begun developing a family of mini-robots optimized for additional operations such as hernia repair, gallbladder removal, hysterectomy, sleeve gastrectomy and others, potentially enabling millions more surgical procedures each year. With its foundational intellectual property—including more than 200 patents and applications—Virtual Incision is poised to lead the next wave of innovation in robotic-assisted surgery with the pioneering MIRA system.
About the MIRA® Surgical Platform
Virtual Incision’s MIRA (“miniaturized in vivo robotic assistant”) Surgical Platform features a small, self-contained surgical device that is inserted through a single midline umbilical incision in the patient’s abdomen. Virtual Incision’s technology is designed to support multi-quadrant abdominal surgeries utilizing existing minimally invasive tools and techniques familiar to laparoscopic surgeons, and does not require a dedicated operating room or specialized infrastructure. Because of its much smaller size, the device is expected to be significantly less expensive than existing robotically-assisted surgical devices.
About Virtual Incision
Virtual Incision is reimagining robotically-assisted surgery, with simple innovations offering mobility, flexibility, and accessibility to provide minimally invasive options to more patients. The company is developing the MIRA Surgical Platform, a first-of-its-kind miniaturized surgical device, focusing first on colon resection, with follow-on specialty robots for additional potential applications. The company is headquartered in Lincoln, Neb.
Back to HCB News
